Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of “Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned an average rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $20.40.

A number of brokerages have issued reports on ARTV. Wedbush restated an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Cantor Fitzgerald cut their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, March 25th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday, April 8th.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ARTV. China Universal Asset Management Co. Ltd. purchased a new position in Artiva Biotherapeutics during the fourth quarter worth about $52,000. Wells Fargo & Company MN increased its stake in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after acquiring an additional 7,151 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth about $166,000. Finally, Deutsche Bank AG acquired a new stake in shares of Artiva Biotherapeutics in the fourth quarter worth approximately $216,000.

Artiva Biotherapeutics Stock Up 3.0 %

NASDAQ:ARTV opened at $2.44 on Friday. Artiva Biotherapeutics has a 52-week low of $1.78 and a 52-week high of $17.31. The stock has a fifty day simple moving average of $3.39 and a 200-day simple moving average of $7.17.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.